Vaxxinova celebrates the approval of the new vaccine production facility for coccidiosis
Sao Paulo, November 2024 – Vaxxinova Brasil has approved its new vaccine facility in lbiuna, Sao Paulo, dedicated to the production of live vaccines against avian coccidiosis. With 4,000 m2 of constructed area and an annual production capacity of more than five times the current one, the project, which began in 2020 and was completed in October 2024, has recently been approved by the Brazilian Ministry of Agriculture (MAPA).
Vaxxinova Brasil also announces the production of Vaxxon Coccivet for broiler, a vaccine applied via spray at the hatchery on the first day of life, specifically designed for biological control of coccidiosis. This solution provides fast and broad-spectrum protection against the main Eimeria species that affect the broiler industry, promoting efficient immunization and contributing to gut health, which contributes with zootechnical performance, explains Jeovane Pereira, Director of Poultry Business.
Combining state-of-the-art technology with the company background on Coccidisis vaccine production, the new facility includes modern air filtration systems, bioreactors, segregated production lines that ensure Good Manufacturing Practices for Biologicals.
We are very pleased with MAPA’s approval of this plant. This project reftects Vaxxinova’s commitment to providing safe and effective solutions for animal health, strengthening our presence in the animal heath poultry market, says Hugo Scanavini Neto, President of Vaxxinova Brasil. The new facility will enable Vaxxinova to produce coccidiosis vaccine for different poultry segments with specific vaccines for broiler, commercial layers, and breeders. The Brazilian vaccine production will supply the domestic market, Latin America and international markets.
